We have investigated
thrombin-stimulated morphological changes and the activation of
phosphoinositide 3-kinase (PI 3-K), as manifested by the accumulation of
PtdIns(3,4)P2 and
PtdIns(3,4,5)P3 (labelled with 32P or myo-[3H]
inositol), in CHRF-288 cells, a leukaemic cell line derived from a platelet progenitor cell. We report that these cells, when exposed to
thrombin or
SFLLRN (the
peptide Ser-
Phe-Leu-Leu-Arg-Asn, a
thrombin-receptor ligand) rapidly change shape, forming membrane '
blebs', detectable by differential interference contrast or confocal microscopy, as well as labelled 3-phosphorylated
phosphoinositides. The '
blebs' are distinguishable from 'ruffles' or lamellae, since they do not contain
phalloidin-detectable actin. Studies with permeabilized cells indicate that PI 3-K is activated synergistically by thrombin+guanosine 5'[gamma-thio]
triphosphate. Two forms of PI 3-K, i.e. PI 3-K(gamma) and p85/PI 3-K, regulated by G beta gamma subunits of
heterotrimeric G-protein and the
small G-protein Rho, respectively, are present in these cells, as is true for platelets.
Wortmannin, a known potent and specific inhibitor of PI 3-K activities, inhibits
thrombin-stiumlated accumulation of 3-phosphorylated
phosphoinositides in a dose-dependent manner (IC50 approximately 10nM), without affecting
phospholipase C activation. Pretreatment of CHRF-288 cells with either
wortmannin (100 nM) or an unrelated synthetic PI 3-K inhibitor,
LY294002 (50 microM), abolishes
thrombin-receptor-stimulated blebbing. These results suggest that
thrombin-stimulated accumulation of 3-phosphorylated
phosphoinositide(s) is required for the shape-change response in CHRF-288 cells.